Alterity Therapeutics (ASX:ATH) has announced that the last patient in its ATH434-201 Phase 2 trial in early-stage multiple system atrophy has completed the study. …
Alterity Therapeutics completes last patient visit in ATH434-201 trial in multiple system atrophy
December 4, 2024 Australian Biotech
Latest Video
New Stories
-
Cartherics appoints Dr Ian Nisbet as CEO as the company accelerates toward clinical trials
December 1, 2025 - - Australian Biotech -
Australian company reports high response rate in trial of off-the-shelf CAR-T therapy
December 1, 2025 - -
Melbourne showcases its health and biomedical strength as leaders gather for National Precincts Summit
December 1, 2025 - - Australian Biotech -
Pharmac to expand emergency medicine access for rural and remote communities
December 1, 2025 - - Latest News -
Tetratherix joint venture secures Alcon partnership to accelerate ophthalmic biomaterials
December 1, 2025 - - Australian Biotech -
MSD to bring vaccine distribution back in-house after 40-year partnership
December 1, 2025 - - Latest News -
New PBS listing offers fresh hope for Australians living with debilitating skin condition
December 1, 2025 - - Latest News